WORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from Nasdaq
WORK Medical Technology Group (NASDAQ: WOK) received a Nasdaq determination letter dated October 9, 2025 notifying the company of a delisting due to its Class A ordinary shares having a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025.
Unless appealed, trading will be suspended at the open of business on October 20, 2025 and a Form 25-NSE will be filed to remove the company’s securities from Nasdaq. The company may request a hearing by October 16, 2025; a hearing request will stay the suspension. The company plans to appeal by October 16 and said it will consider options to regain compliance, including a possible reverse share split.
WORK Medical Technology Group (NASDAQ: WOK) ha ricevuto una lettera di determinazione NASDAQ datata 9 ottobre 2025 che informa della delisting poiché le sue azioni ordinarie di Classe A hanno chiuso con un prezzo di offerta pari a $0,10 o meno per dieci giorni di negoziazione consecutivi che terminano l'8 ottobre 2025.
A meno che non venga presentato ricorso, la negoziazione sarà sospesa all’apertura delle contrattazioni il 20 ottobre 2025 e verrà presentato un modulo Form 25-NSE per rimuovere i titoli della società da Nasdaq. La società può richiedere un’udienza entro il 16 ottobre 2025; una richiesta di udienza sospenderà la sospensione. La società prevede di presentare ricorso entro il 16 ottobre e ha detto che valuterà opzioni per riacquistare la conformità, inclusa una possibile scissione inversa delle azioni.
Grupo de Tecnología Médica WORK (NASDAQ: WOK) recibió una carta de determinación de Nasdaq con fecha 9 de octubre de 2025 notificando la salida de la cotización debido a que sus acciones ordinarias de Clase A cerraron con un precio de oferta de $0,10 o menos durante diez días hábiles consecutivos que terminan el 8 de octubre de 2025.
A menos que se presente un recurso, las operaciones se suspenderán al inicio de la sesión del 20 de octubre de 2025 y se presentará un Form 25-NSE para retirar los valores de la empresa de Nasdaq. La empresa puede solicitar una audiencia antes del 16 de octubre de 2025; una solicitud de audiencia suspenderá la suspensión. La empresa planea apelar antes del 16 de octubre y ha dicho que considerará opciones para recuperar el cumplimiento, incluida una posible desinversión inversa de acciones.
WORK Medical Technology Group(NASDAQ: WOK)은 2025년 10월 9일자로 된 나스닥 결정 서한을 받았으며, 2025년 10월 8일 종료의 10거래일 동안 종가가 $0.10 이하였기 때문에 보통주(Class A)의 상장폐지 통보를 받았습니다.
항소하지 않으면 거래는 2025년 10월 20일 영업시작에 맞춰 중단되며, 나스닥에서 회사의 증권을 제거하기 위해 Form 25-NSE가 제출됩니다. 회사는 2025년 10월 16일까지 청문을 신청할 수 있으며, 청문 신청은 중단을 정지시킵니다. 회사는 10월 16일까지 항소할 계획이며, 준수 회복을 위한 옵션을 검토할 예정이며, 가능하면 주식 재분할도 포함됩니다.
WORK Medical Technology Group (NASDAQ: WOK) a reçu une lettre de décision de Nasdaq datée du 9 octobre 2025 l’informant de la radiation de la cote en raison d’un cours de clôture pour l’action ordinaire de Classe A inférieur ou égal à $0,10 pendant dix jours de négociation consécutifs se terminant le 8 octobre 2025.
Sauf appel, les transactions seront suspendues à l’ouverture des échanges le 20 octobre 2025 et un Form 25-NSE sera déposé pour retirer les titres de la société du Nasdaq. La société peut demander une audience d’ici le 16 octobre 2025; une demande d’audience suspendra la suspension. La société prévoit faire appel d’ici le 16 octobre et a indiqué qu’elle envisagerait des options pour retrouver la conformité, y compris une possible dés. action inversée.
WORK Medical Technology Group (NASDAQ: WOK) erhielt ein Nasdaq-Bestätigungsschreiben vom 9. Oktober 2025, das das Unternehmen über eine Delisting informiert, weil der Schlusskurs der Class-A-Stammaktien $0,10 oder weniger über zehn aufeinanderfolgende Handelstage endete, die am 8. Oktober 2025 endeten.
Sofern kein Widerspruch eingelegt wird, wird der Handel zum Handelsbeginn am 20. Oktober 2025 ausgesetzt und ein Form 25-NSE wird eingereicht, um die Wertpapiere des Unternehmens von Nasdaq zu entfernen. Das Unternehmen kann bis zum 16. Oktober 2025 eine Anhörung beantragen; eine beantragte Anhörung wird die Aussetzung aufheben. Das Unternehmen plant, bis zum 16. Oktober Berufung einzulegen und hat mitgeteilt, dass es Optionen zur Wiedererlangung der Konformität prüfen werde, einschließlich einer möglichen umgekehrten Aktienteilung.
WORK Medical Technology Group (NASDAQ: WOK) تلقت رسالة قرار من Nasdaq مؤرخة 9 أكتوبر 2025 تُخطِر الشركة بإدراجها من التداول بسبب أن أسهمها العادية من الفئة أ أغلقت بسعر عروض قدره $0.10 أو أقل لمدة عشرة أيام تداول متتالية تنتهي في 8 أكتوبر 2025.
ما لم يتم appeal، سيتم تعليق التداول عند افتتاح التداول في 20 أكتوبر 2025 وسيتم تقديم Form 25-NSE لإزالة أوراق الشركة من Nasdaq. يمكن للشركة طلب جلسة استماع بحلول 16 أكتوبر 2025؛ ستؤدي طلب جلسة الاستماع إلى إيقاف التعليق. تخطط الشركة للطعن بحلول 16 أكتوبر وقالت إنها ستنظر في خيارات لاستعادة الامتثال، بما في ذلك احتمال إعادة تقسيم الأسهم.
WORK Medical Technology Group (NASDAQ: WOK) 收到纳斯达克于2025年10月9日发出的决定函，通知公司因其A类普通股在2025年10月8日结束的连续十个交易日的收盘报价为$0.10 或更低而被退市。
若不提起上诉，交易将于2025年10月20日开市时暂停，且将提交Form 25-NSE以将公司证券从纳斯达克除名。公司可在2025年10月16日前请求聆讯；请求聆讯将中止暂停。公司计划在10月16日之前提出上诉，并表示将考虑恢复合规性的选项，包括可能的反向股票拆分。
- Right to request a Nasdaq hearing by October 16, 2025
- Filing a hearing request will stay suspension pending decision
- Company plans to appeal the Nasdaq determination by October 16, 2025
- Nasdaq determined delisting after shares closed ≤ $0.10 for ten trading days
- Trading suspension scheduled at open on October 20, 2025
- Company faces removal via Form 25-NSE to delist securities
Insights
Nasdaq determined to delist WORK Medical for a sub-<$0.10 bid; company will appeal and faces suspension on
WORK Medical received a Nasdaq delisting determination because its Class A ordinary shares had a closing bid of
The company has a procedural remedy: it may request a hearing by the Nasdaq Hearings Panel by
Key near-term items to watch: the formal hearing request by
Hangzhou, China, Oct. 14, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that the Company received a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company of Nasdaq’s determination to delist the Company’s Class A ordinary shares from The Nasdaq Capital Market, because the Company’s Class A ordinary shares had a closing bid price of
Pursuant to the Letter, unless the Company requests an appeal, trading of the Company’s Class A ordinary shares will be suspended at the opening of business on October 20, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq.
The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by October 16, 2025. A request for a hearing will stay the suspension of the Company’s securities pending the Panel’s decision. The Company plans to appeal the determination to the Panel on or before October 16, 2025.
The Company will consider all available options to regain compliance with the Nasdaq Listing Rules for continued listing on Nasdaq, including, if appropriate, implementing a reverse share split.
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
FAQ
Why did Nasdaq issue a delisting determination for WORK Medical (WOK) on October 9, 2025?
What happens to WOK stock if the company does not appeal by October 16, 2025?
How can WORK Medical (WOK) prevent suspension of trading on Nasdaq?
Did WORK Medical (WOK) say it will appeal Nasdaq’s delisting decision?
What remedies did WORK Medical (WOK) say it may use to regain Nasdaq compliance?
When will Nasdaq file Form 25-NSE to remove WORK Medical (WOK) from listing?
